Authors: Sandip Basu Ashwini Kalshetty
Publish Date: 2017/02/24
Volume: 44, Issue: 6, Pages: 1092-1094
Abstract
Amongst differentiated thyroid carcinomas patients with elevated thyroglobulin and negative iodine scintigraphy TENIS demonstrate variable morbidity and mortality and pose clinical challenge to the attending physicians various therapeutics such as tyrosine kinase inhibitors and investigational options eg PRRT or redifferentiation therapy are being examined though a clearcut strategy is yet to evolve 1 2 3 The multitargeted tyrosine kinase inhibitors TKIs eg sorafenib lenvatinib and others an important consideration in the management algorithm have demonstrated a delayed time to disease progression but are limited by a wide range of toxicities The most recent American Thyroid Association ATA guidelines recommendations for their use states their indications as “RAI refractory DTC patients with metastatic rapidly progressive symptomatic and/or imminently threatening disease not otherwise amenable to local control using other approaches” 1 2
Keywords: